Cardiac βarrestin2 Improves Contractility and Adverse Remodeling in Heart Failure, But Is Underexpressed in Humans

Authors

Katie Anne McCrink, Nova Southeastern UniversityFollow
Jennifer Maning, Nova Southeastern UniversityFollow
Angela Vu
Malika Jafferjee
Christine Marrero, Nova Southeastern University
Ava Brill, Nova Southeastern UniversityFollow
Ashley Siryk, Nova Southeastern University

ISBN or ISSN

1558-3597

Publication Title

Journal of the American College of Cardiology

Volume

70

Issue

23

Publication Date / Copyright Date

12-2017

First Page

2948

Last Page

2949

Publisher

Elsevier Inc.

DOI Number

10.1016/j.jacc.2017.10.008

Abstract

In summary, our present study aims to bring the attention of clinicians and pharmacologists to the remarkable functional divergence of the 2 βarrestins in the heart, which, coupled with the virtual absence of the “good” cardiac βarrestin2 protein in humans, highlights potential causes of 2 recent clinical failures of novel, otherwise promising therapies for human HF. Importantly, it points to a “missing link” (boosting endogenous cardiac βarrestin2 levels) for these therapeutics that is necessary to attain efficacy for human HF treatment.

Disciplines

Medicine and Health Sciences | Pharmacy and Pharmaceutical Sciences

Keywords

cardiac βarrestin2, heart failure, humans

NSUWorks Citation

McCrink, Katie Anne; Maning, Jennifer; Vu, Angela; Jafferjee, Malika; Marrero, Christine; Brill, Ava; and Siryk, Ashley, "Cardiac βarrestin2 Improves Contractility and Adverse Remodeling in Heart Failure, But Is Underexpressed in Humans" (2017). Faculty Articles. 166.
https://nsuworks.nova.edu/hpd_corx_facarticles/166